The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells

Holland, M.L.; Panetta, J.A.; Hoskins, J.M.; Bebawy, M.; Roufogalis, B.D.; Allen, J.D.; Arnold, J.C.

doi:10.1016/j.bcp.2005.12.033

Cited by 157Drug Transport and Resistance MechanismsCannabis and Cannabinoid ResearchAntibiotic Resistance in Bacteria

The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells

Holland, M.L., Panetta, J.A., Hoskins, J.M., Bebawy, M., Roufogalis, B.D., Allen, J.D., Arnold, J.C.·2006·Biochemical Pharmacology

DOI 10.1016/j.bcp.2005.12.033

Open this paper in CoChat — free account

Abstract

Cannabis is the most widely used illicit drug in the world. Cannabinoids are used therapeutically by some patients as they have analgesic, anti-emetic and appetite stimulant properties which palliate adverse symptoms. Use of these agents in an oncology setting raises the question of whether they act to modulate the effectiveness of concurrently administered anti-cancer drugs. The transporter, P-glycoprotein (P-gp) confers multiple drug resistance (MDR) by effluxing a diverse array of anti-cancer agents. This study was undertaken to examine the effect of cannabinoids on P-gp. Unlike the known P-gp inhibitor, PSC833, short 1h exposure to three plant-derived cannabinoids, cannabinol (CBN), cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC) and the synthetic cannabinoid receptor agonist, WIN55, 212-2 (WIN) did not inhibit the efflux of the P-gp substrate Rhodamine 123 (Rh123) in either a drug-selected human T lymphoblastoid leukaemia cell line (CEM/VLB(100)) or in a mouse fibroblast MDR1 transfected cell line (77.1). However, in CEM/VLB(100) cells, prolonged 72 h exposure to the cannabinoids, THC and CBD, decreased P-gp expression to a similar extent as the flavonoid, curcumin (turmeric). This correlated with an increase in intracellular accumulation of Rh123 and enhanced sensitivity of the cells to the cytotoxic actions of the P-gp substrate, vinblastine. Taken together, these results provide preliminary evidence that cannabinoids do not exacerbate P-gp mediated MDR. Further, plant-derived cannabinoids are moderately effective in reversing MDR in CEM/VLB(100) cells by decreasing P-gp expression.

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2005.12.033

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Preclinical studies have reported that cannabinoids may also bind membrane transporters including breast cancer resistance protein and P-gp, which can, theoretically, impact the effect of other medications.
“Preclinical studies have reported that cannabinoids may also bind membrane transporters including breast cancer resistance protein111 and P-gp,112,113 which can, theoretically, impact the effect of other medications.”
From Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions (2024) · cites this paper as [112]

THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE
Endicott, J. A., & Ling, V. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.001033 · Cited by 2,071 · see citing works
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,545 · see citing works
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,489 · see citing works
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315 · see citing works
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A. T., Willingham, M. C., Lai, S.-L., Gazdar, A. F., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290 · see citing works
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews. Cancer · doi:10.1038/nrc1188 · Cited by 740 · see citing works
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen, J. D., van Loevezijn, A., Rademaker-Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G., & Schinkel, A. H. (2002) · PubMed · Cited by 690 · see citing works
Self-citation
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J. K., Grever, M. R., Appelbaum, F. R., et al. (1999) · PubMed · doi:10.1182/blood.v94.3.1086.415k32_1086_1099 · Cited by 573 · see citing works
Cannabis: pharmacology and toxicology in animals and humans
Adams, I. B., & Martin, B. R. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911115852.x · Cited by 570 · see citing works
Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein.
Cornwell, M. M., Pastan, I. H., & Gottesman, M. M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61633-3 · Cited by 530 · see citing works
Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis [see comments]
Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., TSURUO, T., Troncy, J., Treille, D., & Fiere, D. M. (1992) · Blood · doi:10.1182/blood.v79.2.473.473 · Cited by 486 · see citing works
Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.
Beck, W. T., Mueller, T. J., & Tanzer, L. R. (1979) · PubMed · Cited by 476 · see citing works
The endocannabinoid system: a general view and latest additions
PETROCELLIS, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 473 · see citing works
The Inheritance of Chemical Phenotype in Cannabis sativa L.
de Meijer, E. P. M., Bagatta, M., Carboni, A., Crucitti, P., Moliterni, V. M. C., Ranalli, P., & Mandolino, G. (2003) · Genetics · doi:10.1093/genetics/163.1.335 · Cited by 356 · see citing works
Antineoplastic Activity of Cannabinoids2
Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L., & Carchman, R. A. (1975) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/55.3.597 · Cited by 349 · see citing works
Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors
Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., & Finazzi‐Agrò, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005722200 · Cited by 347 · see citing works
Analgesic Effect of the Synthetic Cannabinoid CT-3 on Chronic Neuropathic Pain: A Randomized Controlled Trial
Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003) · JAMA · doi:10.1001/jama.290.13.1757 · Cited by 340 · see citing works
Cannabis: pharmacology and toxicology in animals and humans
Adams, I. B., & Martin, B. R. (1996) · Addiction · doi:10.1111/j.1360-0443.1996.tb02264.x · Cited by 335 · see citing works
Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells
Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V., & Limtrakul, P. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01224-8 · Cited by 291 · see citing works
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
McKallip, R. J., Lombard, C. A., Fisher, M. T., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, P. S., & Nagarkatti, M. (2002) · Blood · doi:10.1182/blood-2002-01-0098 · Cited by 288 · see citing works
Possible endocannabinoid control of colorectal cancer growth
Ligresti, A., Bisogno, T., Matias, I., PETROCELLIS, L. D., Cascio, M. G., Cosenza, V., D’Argenio, G., Scaglione, G., Bifulco, M., Sorrentini, I., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00881-3 · Cited by 288 · see citing works
Molecular mechanisms of drug resistance
Hayes, J. D., & Wolf, C. R. (1990) · Biochemical Journal · doi:10.1042/bj2720281 · Cited by 279 · see citing works
Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments]
Arceci, R. J. (1993) · Blood · doi:10.1182/blood.v81.9.2215.2215 · Cited by 226 · see citing works
Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A
Twentyman, P. R., & Bleehen, N. M. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90435-g · Cited by 211 · see citing works
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
Jin, S. V., Gorfajn, B., Faircloth, G. T., & Scotto, K. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6775 · Cited by 206 · see citing works
Subcellular Localization and Activity of Multidrug Resistance Proteins
Rajagopal, A., & Simon, S. M. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0704 · Cited by 190 · see citing works
Targeting the endocannabinoid system in cancer therapy: A call for further research
Bifulco, M., & Marzo, V. D. (2002) · Nature Medicine · doi:10.1038/nm0602-547 · Cited by 171 · see citing works
Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells
Melck, D., Rueda, D., Galve-Roperh, I., De Petrocellis, L., Guzmán, M., & Di Marzo, V. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01639-7 · Cited by 168 · see citing works
Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments]
Arceci, R. J. (1993) · Blood · doi:10.1182/blood.v81.9.2215.bloodjournal8192215 · Cited by 165 · see citing works
Established and potential therapeutic applications of cannabinoids in oncology
Walsh, D., Nelson, K. A., & Mahmoud, F. A. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-002-0387-7 · Cited by 164 · see citing works
Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids
Limtrakul, P., Anuchapreeda, S., & Buddhasukh, D. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-13 · Cited by 145 · see citing works
Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs.
Azorlosa, J. L., Heishman, S. J., Stitzer, M. L., & Mahaffey, J. M. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10949-x · Cited by 117 · see citing works
Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts
Sarker, K. P., & Maruyama, I. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3055-2 · Cited by 104 · see citing works
Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates.
Molnár, J., Szabó, D., Pusztai, R., Mucsi, I., Berek, L., Ocsovszki, I., Kawata, E., & Shoyama, Y. (2000) · PubMed · Cited by 91 · see citing works
Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway
Powles, T. B., Poele, R. T., Shamash, J., Chaplin, T., PROPPER, D. J., Joel, S., Oliver, R. T. D., & Liu, W. M. (2004) · Blood · doi:10.1182/blood-2004-03-1182 · Cited by 90 · see citing works
Ecteinascidin-743 inhibits activated but not constitutive transcription.
Friedman, D., Hu, Z., Kolb, E. A., Gorfajn, B., & Scotto, K. W. (2002) · PubMed · Cited by 89 · see citing works
Subcellular Detection and Localization of the Drug Transporter P-Glycoprotein in Cultured Tumor Cells
Molinari, A., Calcabrini, A., Meschini, S., Stringaro, A., Crateri, P., Toccacieli, L., Marra, M., Colone, M., Cianfriglia, M., & Arancia, G. (2002) · Current Protein and Peptide Science · doi:10.2174/1389203023380413 · Cited by 78 · see citing works
Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.
Martin, B. R., & Wiley, J. L. (2004) · PubMed · Cited by 65 · see citing works
Dynamic and intracellular trafficking of P‐glycoprotein‐EGFP fusion protein: Implications in multidrug resistance in cancer
Fu, D., Bebawy, M., Kable, E., & Roufogalis, B. D. (2004) · International Journal of Cancer · doi:10.1002/ijc.11659 · Cited by 65 · see citing works
Self-citation
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
Ross, D. D. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.014 · Cited by 50 · see citing works
AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun
Faubert, B. L., & Kaminski, N. E. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.2.259 · Cited by 50 · see citing works
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Warner, E., Hedley, D. W., Andrulis, I. L., Myers, R. E., Trudeau, M. G., Warr, D. G., Pritchard, K. I., Blackstein, M. E., Goss, P. E., Franssen, E., et al. (1998) · PubMed · Cited by 48 · see citing works
Cannabinoids and Cancer
Kogan, N. M. (2005) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955705774329555 · Cited by 48 · see citing works
Selective modulation of P-glycoprotein-mediated drug resistance
Bebawy, M., Morris, M. B., & Roufogalis, B. D. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2184 · Cited by 42 · see citing works
Self-citation
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
ROSS, D. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/s1521-6926(04)00080-5 · Cited by 37 · see citing works
Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill, A. B., Beck, W. T., & Trent, J. M. (1988) · PubMed · Cited by 23 · see citing works
Medicinal cannabis extracts for the treatment of multiple sclerosis.
Smith, P. F. (2004) · PubMed · Cited by 20 · see citing works

Flagged first, then by citations

Sorted by citations

Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works
Cannabidiol—recent advances
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · see citing works
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 479 · see citing works
Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells
Bebawy, M., Combes, V., Lee, E., Jaiswal, R., Gong, J., Bonhoure, A., & Grau, G. E. (2009) · Leukemia · doi:10.1038/leu.2009.76 · Cited by 323 · see citing works
Self-citation
P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review
Abdallah, H. M., Al-Abd, A. M., El-Dine, R. S., & Halawany, A. M. E. (2014) · Journal of Advanced Research · doi:10.1016/j.jare.2014.11.008 · Cited by 320 · see citing works
Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
Nabissi, M., Morelli, M. B., Santoni, M., & Santoni, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs328 · Cited by 248 · see citing works
Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis
Tomko, A. M., Whynot, E. G., Ellis, L. D., & Dupré, D. J. (2020) · Cancers · doi:10.3390/cancers12071985 · Cited by 231 · see citing works
Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery
Nasr, M. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1092619 · Cited by 208 · see citing works
Cannabinoids: Occurrence and Medicinal Chemistry
Appendino, G., Chianese, G., & Taglialatela‐Scafati, O. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794940888 · Cited by 209 · see citing works
Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Wu, C., Ohnuma, S., & Ambudkar, S. V. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163887 · Cited by 172 · see citing works
Medicinal Cannabis—Potential Drug Interactions
Alsherbiny, M. A., & Li, C. G. (2018) · Medicines · doi:10.3390/medicines6010003 · Cited by 164 · see citing works
The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids
Holland, M. L., Lau, D. T. T., Allen, J. D., & Arnold, J. C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707467 · Cited by 150 · see citing works
Self-citation
Cannabinoids as anticancer drugs: current status of preclinical research
Hinz, B., & Ramer, R. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01727-4 · Cited by 150 · see citing works
Anti‐tumour actions of cannabinoids
Hinz, B., & Ramer, R. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14426 · Cited by 146 · see citing works
Marijuana Use in Patients With Cardiovascular Disease
DeFilippis, E. M., Bajaj, N. S., Singh, A., Malloy, R. J., Givertz, M. M., Blankstein, R., Bhatt, D. L., & Vaduganathan, M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.025 · Cited by 141 · see citing works
The complications of promiscuity: endocannabinoid action and metabolism
Alexander, S. P. H., & Kendall, D. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707456 · Cited by 133 · see citing works
The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?
Moreno, E., Cavic, M. R., Krivokuća, A., Casadó, V., & Canela, E. I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00339 · Cited by 126 · see citing works
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)
Tournier, N., Chevillard, L., Mégarbane, B., Pirnay, S., Scherrmann, J., & Declèves, X. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990848 · Cited by 125 · see citing works
The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids
McAllister, S. D., Soroceanu, L., & Desprez, P. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9608-y · Cited by 139 · see citing works
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications
Qian, Y., Gurley, B. J., & Markowitz, J. S. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001089 · Cited by 123 · see citing works
Insights into the effects of the endocannabinoid system in cancer: a review
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., & Torres‐Suárez, A. I. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14331 · Cited by 114 · see citing works
CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer
Fraguas‐Sánchez, A. I., Fernández-Carballido, A. M., Simancas-Herbada, R., Martín‐Sabroso, C., & Torres‐Suárez, A. I. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118916 · Cited by 108 · see citing works
Antihyperalgesic effect of a <i>Cannabis sativa</i> extract in a rat model of neuropathic pain: mechanisms involved
Comelli, F., Giagnoni, G., Bettoni, I., Colleoni, M., & Costa, B. (2008) · Phytotherapy Research · doi:10.1002/ptr.2401 · Cited by 103 · see citing works
Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms
Júnior, R. G. D. O., Adrielly, A. F. C., Almeida, J. R. G. D. S., Grougnet, R., Thiéry, V., & Picot, L. (2018) · Fitoterapia · doi:10.1016/j.fitote.2018.02.025 · Cited by 96 · see citing works
Cannabinoids as anticancer therapeutic agents
Kovalchuk, O., & Kovalchuk, I. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1742952 · Cited by 96 · see citing works
Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators
Brown, I. M., Cascio, M. G., Rotondo, D., Pertwee, R. G., Heys, S. D., & Wahle, K. W. J. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.10.001 · Cited by 94 · see citing works
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics
Cox, E. J., Maharao, N. V., Patilea-Vrana, G., Unadkat, J. D., Rettie, A. E., McCune, J. S., & Paine, M. F. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.001 · Cited by 91 · see citing works
Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities
Lal, S., Shekher, A., Puneet, Narula, A. S., Abrahamse, H., & Gupta, S. C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105302 · Cited by 89 · see citing works
Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients
Božina, N., Kuzman, M. R., Medved, V., Jovanović, N., Sertić, J., & Hotujac, L. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.002 · Cited by 85 · see citing works
Targeting multidrug resistance in cancer by natural chemosensitizers
Hamed, A. R., Abdel‐Azim, N. S., Shams, K. A., & Hammouda, F. M. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0043-8 · Cited by 84 · see citing works
Cannabidiol-Δ 9 -tetrahydrocannabinol interactions on acute pain and locomotor activity
Britch, S. C., Wiley, J. L., Yu, Z., Clowers, B. H., & Craft, R. M. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.046 · Cited by 83 · see citing works
Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways
Muthusamy, G., Kanimozhi, G., Bharathiraja, P., Khan, H. A., Alhomida, A. S., Ekhzaimy, A. A., Brindha, G., & Prasad, N. R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111632 · Cited by 82 · see citing works
Cannabinoids as Anticancer Drugs
Ramer, R., & Hinz, B. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.04.002 · Cited by 80 · see citing works
Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study
Feinshtein, V., Erez, O., Ben‐Zvi, Z., Eshkoli, T., Sheizaf, B., Sheiner, E., & Holcberg, G. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.08.005 · Cited by 77 · see citing works
Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78 · see citing works
“110 Preclinical studies have reported that cannabinoids may also bind membrane transporters including breast cancer resistance protein 111 and P-gp, 112,113 which can, theoretically, impact the effect of other medications.”
Background
Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines
Feinshtein, V., Erez, O., Ben‐Zvi, Z., Erez, N., Eshkoli, T., Sheizaf, B., Sheiner, E., Huleihel, M., & Holcberg, G. (2013) · PeerJ · doi:10.7717/peerj.153 · Cited by 72 · see citing works
Pharmacological Synergism Between Cannabinoids and Paclitaxel in Gastric Cancer Cell Lines
Miyato, H., Kitayama, J., Yamashita, H., Souma, D., Asakage, M., Yamada, J., & Nagawa, H. (2008) · Journal of Surgical Research · doi:10.1016/j.jss.2008.06.045 · Cited by 73 · see citing works
Modulation of the Endocannabinoid System as a Potential Anticancer Strategy
Ramer, R., Schwarz, R., & Hinz, B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00430 · Cited by 73 · see citing works
Enhanced Brain Disposition and Effects of Δ9-Tetrahydrocannabinol in P-Glycoprotein and Breast Cancer Resistance Protein Knockout Mice
Spiro, A. S., Wong, A., Boucher, A. A., & Arnold, J. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035937 · Cited by 61 · see citing works
Self-citation
Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology
Turgeman, I., & Bar‐Sela, G. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1561859 · Cited by 61 · see citing works
Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations
Anderson, L. L., Etchart, M. G., Bahceci, D., Golembiewski, T. A., & Arnold, J. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-94212-6 · Cited by 58 · see citing works
Self-citation
Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome
Anderson, L. L., Ametovski, A., Luo, J. L., Everett‐Morgan, D., McGregor, I. S., Banister, S. D., & Arnold, J. C. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00677 · Cited by 57 · see citing works
Self-citation
Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer
Tomko, A. M., O’Leary, L. F., Trask, H., Achenbach, J. C., Hall, S. R., Goralski, K. B., Ellis, L. D., & Dupré, D. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01124 · Cited by 52 · see citing works
Potential Pharmacokinetic Drug‐Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain
Vázquez, M., Guevara, N., Maldonado, C., Guidó, P. C., & Schaiquevich, P. S. (2020) · BioMed Research International · doi:10.1155/2020/3902740 · Cited by 56 · see citing works
CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells
Arnold, J. C., Hone, P., Holland, M. L., & Allen, J. D. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70871-x · Cited by 50 · see citing works
Self-citation
ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice
Brzozowska, N., Li, K. M., Wang, X., Booth, J., Stuart, J. M., McGregor, I. S., & Arnold, J. C. (2016) · PeerJ · doi:10.7717/peerj.2081 · Cited by 49 · see citing works
Self-citation
The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid–Antipsychotic Drug Interactions
Brzozowska, N., de Tonnerre, E. J., Li, K. M., Wang, X., Boucher, A. A., Callaghan, P. D., Kuligowski, M., Wong, A. C. H., & Arnold, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.50 · Cited by 49 · see citing works
Self-citation
Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol
Olivas-Aguirre, M., Torres-López, L., Pottosin, I. I., & Dobrovinskaya, O. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617937 · Cited by 47 · see citing works
Cannabinoid receptor ligands as potential anticancer agents – high hopes for new therapies?
Oesch, S., & Gertsch, J. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.07.0002 · Cited by 45 · see citing works
The Yin and Yang of Cannabis-induced Psychosis: the Actions of Δ 9-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia
Arnold, J. C., Boucher, A. A., & Karl, T. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884726 · Cited by 43 · see citing works
Self-citation
Antitumorigenic targets of cannabinoids – current status and implications
Ramer, R., & Hinz, B. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1177512 · Cited by 43 · see citing works
Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas
Fraguas‐Sánchez, A. I., Fernández-Carballido, A. M., & Torres‐Suárez, A. I. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1236913 · Cited by 43 · see citing works
Biological effects of cannabidiol on human cancer cells: Systematic review of the literature
Valenti, C., Billi, M., Pancrazi, G. L., Calabria, E., Armogida, N. G., Tortora, G., Pagano, S., Barnaba, P., & Marinucci, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106267 · Cited by 42 · see citing works
Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles
Fraguas‐Sánchez, A. I., Fernández-Carballido, A. M., Delié, F., Cohen, M., Martín‐Sabroso, C., Mezzanzanica, D., Figini, M., Satta, A., & Torres‐Suárez, A. I. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.07.008 · Cited by 40 · see citing works
Oral delivery of cannabidiol: Revealing the formulation and absorption challenges
Šitovs, A., Logviss, K., Lauberte, L., & Mohylyuk, V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105316 · Cited by 40 · see citing works
Functional Expression of Drug Transporters in Glial Cells
Ashraf, T., Kao, A. C.-C., & Bendayan, R. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.010 · Cited by 36 · see citing works
Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics
Buchtová, T., Lukáč, D., Škrott, Z., Chromá, K., Bártek, J., & Mistrík, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032885 · Cited by 37 · see citing works
Gamma-linolenic acid modulates the response of multidrug-resistant K562 leukemic cells to anticancer drugs
Kong, X., Ge, H., Chen, L., Liu, Z., Yin, Z., Li, P., & Li, M. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.02.010 · Cited by 34 · see citing works
Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review
Bouquié, R., Deslandes, G., Mazaré, H., Cogné, M., Mahé, J., Grégoire, M., & Jolliet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12373 · Cited by 34 · see citing works
Therapeutic potential of cannabinoids in combination cancer therapy
Malhotra, P., Casari, I., & Falasca, M. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100774 · Cited by 33 · see citing works
CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen
Prather, P. L., FrancisDevaraj, F., Dates, C. R., Greer, A. K., Bratton, S. M., Ford, B. M., Franks, L. N., & Radominska-p, A. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.057 · Cited by 31 · see citing works
Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions
Auzmendi, J., Palestro, P. H., Blachman, A., Gavernet, L., Merelli, A., Talevi, A., Calabrese, G. C., Ramos, A. J., & Lazarowski, A. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.00032 · Cited by 30 · see citing works
Neuroprotection Following Concussion: The Potential Role for Cannabidiol
Singh, J., & Neary, J. P. (2020) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2020.23 · Cited by 30 · see citing works
Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells
Inkol, J. M., Hocker, S. E., & Mutsaers, A. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255591 · Cited by 30 · see citing works
Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment
Woerdenbag, H. J., Olinga, P., Kok, E. A., Brugman, D. A. P., van Ark, U. F., Ramcharan, A. S., Lebbink, P. W., Hoogwater, F. J. H., Knapen, D. G., de Groot, D. J. A., et al. (2023) · Cancers · doi:10.3390/cancers15072119 · Cited by 30 · see citing works
Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs
Sun, Y., Zhang, T., Gao, P., Meng, B., Gao, Y., Wang, X., Zhang, J., Wang, H., Wu, X., Zheng, W., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0513-z · Cited by 30 · see citing works
Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB 1 cannabinoid receptor agonists
Pryce, G., Visintin, C., Ramagopalan, S. V., Al‐Izki, S., Faveri, L. E. D., Nuamah, R. A., Mein, C. A., Montpetit, A., Hardcastle, A. J., Kooij, G., et al. (2013) · The FASEB Journal · doi:10.1096/fj.13-239442 · Cited by 29 · see citing works
Antimicrobial and Cytotoxic Effects of Cannabinoids: An Updated Review with Future Perspectives and Current Challenges
Saleemi, M. A., Yahaya, N., Zain, N. N. M., Raoov, M., Yong, Y. K., Noor, N. S., & Lim, V. (2022) · Pharmaceuticals · doi:10.3390/ph15101228 · Cited by 29 · see citing works
Endocannabinoid System and Tumour Microenvironment: New Intertwined Connections for Anticancer Approaches
Iozzo, M., Sgrignani, G., Comito, G., Chiarugi, P., & Giannoni, E. (2021) · Cells · doi:10.3390/cells10123396 · Cited by 28 · see citing works
Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies
Wang, F., & Multhoff, G. (2021) · Biomolecules · doi:10.3390/biom11040582 · Cited by 28 · see citing works
Reviewing the mechanisms of natural product-drug interactions involving efflux transporters and metabolic enzymes
Feltrin, C., & Simões, C. M. O. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108825 · Cited by 26 · see citing works
A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies
Birer-Williams, C. M. C., Gufford, B. T., Chou, E., Alilio, M., VanAlstine, S., Morley, R. E., McCune, J. S., Paine, M. F., & Boyce, R. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000054 · Cited by 26 · see citing works
Cannabidiol drug interaction considerations for prescribers and pharmacists
Graham, M., Martin, J. H., Lucas, C. J., Murnion, B. P., & Schneider, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2142114 · Cited by 26 · see citing works
Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?
Rocha, L., Frías‐Soria, C. L., Ortíz, J. G., Auzmendi, J., & Lazarowski, A. (2020) · Epilepsia Open · doi:10.1002/epi4.12376 · Cited by 26 · see citing works
GALNT14 Involves the Regulation of Multidrug Resistance in Breast Cancer Cells
Shan, J., Liu, Y., Wang, Y., Li, Y., Yu, X., & Wu, C. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.04.003 · Cited by 24 · see citing works
Attitudes about and correlates of cannabis legalization policy among U.S. young adults
Rudy, A. K., Barnes, A. J., Cobb, C. O., & Nicksic, N. E. (2020) · Journal of American College Health · doi:10.1080/07448481.2020.1713135 · Cited by 24 · see citing works
Anti-cancer potential of cannabis terpenes in a Taxol-resistant model of breast cancer
Tomko, A. M., Whynot, E. G., O’Leary, L. F., & Dupré, D. J. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0792 · Cited by 20 · see citing works
Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?
Abu-Amna, M., Salti, T., Khoury, M., Cohen, I., & Bar‐Sela, G. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00811-2 · Cited by 20 · see citing works
New Insights into Antimetastatic and Antiangiogenic Effects of Cannabinoids
Ramer, R., & Hinz, B. (2014) · International review of cytology · doi:10.1016/bs.ircmb.2014.10.005 · Cited by 19 · see citing works
Cannabidiol modifies the seizure expression and effects of antiseizure drugs in a rat model of recurrent severe seizures
Frías‐Soria, C. L., Pérez‐Pérez, D., Orozco-Suárez, S. A., & Rocha, L. (2021) · Seizure · doi:10.1016/j.seizure.2021.04.008 · Cited by 18 · see citing works
The Use of Cannabis sativa L. for Pest Control: From the Ethnobotanical Knowledge to a Systematic Review of Experimental Studies
Oña, G., Balant, M., Bouso, J. C., Gras, A., Vallès, J., Vitales, D., & Garnatje, T. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0095 · Cited by 16 · see citing works
From bench to bedside: the application of cannabidiol in glioma
Feng, S., Pan, Y., Lu, P., Li, N., Zhu, W., & Hao, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05477-0 · Cited by 16 · see citing works
The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine
Skórzewska, M., & Gęca, K. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01589-4 · Cited by 29 · see citing works
The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer
Opitz, B. J., Ostroff, M. L., & Whitman, A. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019828920 · Cited by 15 · see citing works
In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters
Kim, S., Choi, W.-G., Kwon, M., Lee, S., Cho, Y., Lee, J. Y., Kang, H. C., Song, I., & Lee, H. S. (2019) · Molecules · doi:10.3390/molecules24163000 · Cited by 15 · see citing works
Effect of cannabinoids on the efficacy and side effects of anticancer therapeutic strategies – Current status of preclinical and clinical research
Ramer, R., & Hinz, B. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108851 · Cited by 15 · see citing works
Phytocannabinoids as Chemotherapy Adjuncts—A Review for Users
Nahler, G. (2024) · Onco · doi:10.3390/onco4040021 · Cited by 12 · see citing works
High incidence of persistent subtherapeutic levels of the most common AEDs in children with epilepsy receiving polytherapy
Czornyj, L. A., Guidó, P. C., Bramuglia, G. F., Rodiño, A., Feria-Romero, I. A., & Lazarowski, A. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.09.008 · Cited by 13 · see citing works
In Vitro Screening of Three Commercial Cannabis-Based Products on ATP-Binding Cassette and Solute-Carrier Transporter Function
Anderson, L. L., Etchart, M. G., MacNair, L., Land, M. H., Mosesova, I., Bonn‐Miller, M. O., & Arnold, J. C. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0053 · Cited by 12 · see citing works
Self-citation
Cannabidiol (CBD) as a potential therapeutic agent for liver cancer: a comprehensive review of current evidence
Esmaeli, M., & Dehabadi, M. D. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03870-3 · Cited by 11 · see citing works
Potential Drug Interactions Between Cannabinoids and Its Derivatives and Oral Anticoagulants
Paduch, M., & Thomason, A. R. (2021) · Hospital Pharmacy · doi:10.1177/0018578720985438 · Cited by 10 · see citing works
Anticoagulant drug–drug interactions with cannabinoids: A systematic review
Smythe, M. A., Wu, W. G., & Garwood, C. L. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2881 · Cited by 10 · see citing works
Cannabinoïdes et thérapeutique
Fabresse, N., Becam, J., Carrara, L., Descoeur, J., Mario, M. D., Drevin, G., Duval, T., Hannas, N., Lanot, T., Marillier, M., et al. (2019) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2019.06.002 · Cited by 10 · see citing works
Suppression of αvβ6 downregulates P-glycoprotein and sensitizes multidrug-resistant breast cancer cells to anticancer drugs
Zhang, Y., Gao, Z., DONG, G. H., LI, X., Wu, Y., LI, G., Wang, A., LI, H., & YIN, D. L. (2020) · Neoplasma · doi:10.4149/neo_2020_190604n486 · Cited by 10 · see citing works
The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats
Darweesh, R. S., Khamis, T. N., & El‐Elimat, T. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01878-2 · Cited by 9 · see citing works
Medicinal Cannabis: an overview for health-care providers
Wallach, J. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00005-2 · Cited by 9 · see citing works
Cannabis use and atrial arrhythmias: A systematic review and meta-analysis of large populational studies
Chye, D. M., Rodrigues, T. S., Quarto, L. J. G., Young, N., Hamilton, G. W., Burrell, L. M., Teh, A. W., Lim, H. S., & Koshy, A. N. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.05.062 · Cited by 8 · see citing works
Cannabidiol–drug interaction in cancer patients: A retrospective study in a real‐life setting
Guédon, M., Bozec, A. L., Brügel, M., Clarenne, J., Carlier, C., Perrier, M., Laurent, M., Hettler, D., Mongaret, C., Bouché, O., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15701 · Cited by 8 · see citing works
Combination of approved chemotherapeutics and natural products for topoisomerase II targeting: efficacy and safety in cancer therapy
El‐Far, A. H., Elfadadny, A., Ragab, R. F., Hamada, R., Elbadawy, M., & Fu, J. (2025) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00208-x · Cited by 9 · see citing works
In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters
Kim, S., Kim, D. K., Shin, Y., Jeon, J.-H., Song, I., & Lee, H. S. (2020) · Molecules · doi:10.3390/molecules25194589 · Cited by 7 · see citing works

CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells
Arnold, J. C., Hone, P., Holland, M. L., & Allen, J. D. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70871-x · Cited by 50 · see citing works
Self-citation
The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids
Holland, M. L., Lau, D. T. T., Allen, J. D., & Arnold, J. C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707467 · Cited by 150 · see citing works
Self-citation
PIII-63The cannabinoid cannabidiol inhibits P-glycoprotein activity
Zhu, H., WANG, J., Markowitz, J. S., Donovan, J., Gibson, B. B., Gefroh, H. A., & DeVane, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.271
Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Zhu, H.-J., Wang, J.-S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., & DeVane, C. L. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098541 · Cited by 192 · see citing works
Modulation of P‐glycoprotein activity by cannabinoid molecules in HK‐2 renal cells
Nieri, P., Romiti, N., Adinolfi, B., Chicca, A., Massarelli, I., & Chieli, E. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706778 · Cited by 36 · see citing works

Authors: Holland, M. L., Panetta, J. A., Hoskins, J. M., Bebawy, M., Roufogalis, B. D., Allen, J. D., & Arnold, J. C.
Affiliations: The University of Sydney (AU)
Centenary Institute (AU)
Corresponding author: Arnold, J.C.
ORCID: Holland, M.L.
Bebawy, M.
Roufogalis, B.D.
Arnold, J.C.
Venue: Biochemical Pharmacology
Publisher: Elsevier BV
Published: 2006-04
Volume: 71
Issue: 8
Pages: 1146-1154
ISSN: 0006-2952 (ISSN-L)
DOI: 10.1016/j.bcp.2005.12.033
OpenAlex: W2133500154
Cited by: 157
References: 47
Citations by year: 2026: 3 · 2025: 9 · 2024: 9 · 2023: 12 · 2022: 16 · 2021: 14 · 2020: 20 · 2019: 13 · 2018: 10 · 2017: 3 · 2016: 10 · 2015: 2 · 2014: 3 · 2013: 10 · 2012: 5
FWCI: 2.43
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biochemical Pharmacology (publishedVersion)
PubMed (publishedVersion)
UTS ePRESS (University of Technology Sydney) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
Keywords: cannabinoids, P-glycoprotein, multidrug resistance, drug efflux, cannabinol, cannabidiol, tetrahydrocannabinol, WIN 55,212-2, curcumin, rhodamine 123, vinblastine, MDR1, drug resistance reversal
MeSH terms: Antineoplastic Agents, Cannabinoids, Cell Survival, Dose-Response Relationship, Drug, Humans, Drug Resistance, Multiple, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Protein Transport, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks